Nimorazole

Nimorazole (K-1900), a 2-nitroimidazole, is a hypoxic cell-radiation sensitizer. Nimorazole has anti-infective and anti-protozoal against trichomoniasis. Nimorazole has the potential for head and neck cancer[1][2].

Product Specifications

CAS Number

[6506-37-2]

Product Name Alternative

K-1900

UNSPSC

12352005

Hazard Statement

H302, H400, H410

Target

Antibiotic; Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Nimorazole.html

Purity

99.33

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=[N+](C1=CN=CN1CCN2CCOCC2)[O-]

Molecular Formula

C9H14N4O3

Molecular Weight

226.23

Precautions

H302, H400, H410

References & Citations

[5]Zohreh Fakhrieh Kashan, et al. Therapeutic effects of Iranian herbal extracts against Trichomonas vaginalis. Iran Biomed J. 2017 Sep;21 (5) :285-93.|[1]Overgaard, J., et al., A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol, 1998. 46 (2) : p. 135-46.|[2]Roy, R.B., S.M. Laird, and L. Heasman, Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole. Br J Vener Dis, 1975. 51 (4) : p. 281-4.|[3]Henk, J.M., K. Bishop, and S.F. Shepherd, Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol, 2003. 66 (1) : p. 65-70.|[4]Peter Wardman, et al. Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes. Br J Radiol. 2019 Jan;92 (1093) :20170915.